Transaction details
Immunome Inc. (NASDAQ: IMNM) reported that Chief Scientific Officer Jack Higgins sold 9,438 shares of the companys common stock on April 2, 2026. The shares were disposed of at $21.64 each, producing a gross transaction value of $204,238.
The disposition was carried out under a pre-arranged Rule 10b5-1 trading plan that Higgins adopted on December 19, 2025. Following the sale, Higgins directly holds 22,000 shares of Immunome common stock.
Related holdings and restrictions
In addition to the shares he holds directly, Higgins indirectly holds custodial positions of 1,000 shares each for three children. Those custodial shares are subject to a lock-up agreement entered into on December 15, 2025, and Higgins has disclaimed beneficial ownership of those custodial holdings.
Market context
At the time of the disclosure the stock was trading near $21.84. The company is carrying a market capitalization of $2.47 billion. Over the past 12 months shares of Immunome have appreciated sharply, rising roughly 250% according to InvestingPro data. Analysts maintain generally bullish views on the stock, with price targets reported in the $30 to $40 range.
Analyst coverage
H.C. Wainwright has begun coverage on Immunome with a Buy rating and a $40.00 price target. In its research note the firm highlighted Immunomes development of a portfolio of oncology assets spanning solid tumor and hematologic indications. The note specifically called out the firms lead candidate, varegacestat, describing it as a potentially superior gamma-secretase inhibitor for desmoid tumors relative to the currently approved therapy, Ogsiveo.
What this filing shows
The SEC filing and subsequent disclosure summarize the mechanics of Higginss sale, the conditions under which it was executed and his remaining direct and indirect holdings. The trade was made under an established 10b5-1 plan, and the custodial shares remain bound by a lock-up agreement.
Bottom line
The filing provides a clear account of the April 2, 2026 insider sale and the status of Higginss holdings. Market participants have multiple reference points from the disclosure including the exercise of a pre-arranged trading plan, current market price and capitalization, recent one-year performance metrics and fresh analyst coverage highlighting the companys oncology pipeline.